The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different genders, races, ages and life histories, chances ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

The study was the first Phase III clinical ... difference in the average length of time the patient survived after diagnosis with advanced, inoperable biliary tract cancer," Shroff said. "Our ...

Based on the strength of these Phase ... Both clinical doses demonstrated improvement relative to placebo over 52 weeks, with the 50 mg dose showing a greater treatment effect. Additional analyses are ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – – Safety Results Consistent with Safety Profile for ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...